Athersys (ATHX) Stock Price, News & Analysis

Company Overview

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 1,004 shs
• Average Volume: 1.77 million shs
• Market Capitalization: $833,000.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ATHX Stock Analysis - Frequently Asked Questions

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) issued its quarterly earnings results on Monday, November, 15th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.00) by $0.25. The biopharmaceutical company had revenue of $4.79 million for the quarter.

When did Athersys' stock split?

Shares of Athersys reverse split on Monday, August 29th 2022. The 1-25 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Athersys?

Shares of ATHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Athersys own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Athersys investors own include Bank of America (BAC), Predictive Oncology (POAI), Ford Motor (F), Agenus (AGEN), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC) and Abbott Laboratories (ABT).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 1/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ATHX
• CUSIP: N/A
• CIK: 1368148
• Web: www.athersys.com
• Phone: (216) 431-9900
• Fax: 216-361-9495
• Employees: 24
• Year Founded: 1995

Profitability

• EPS (Most Recent Fiscal Year): ($2.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-72,530,000.00
• Net Margins: N/A
• Pretax Margin: -46,304.93%
• Return on Equity: N/A
• Return on Assets: -223.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.06
• Quick Ratio: 0.06

Sales & Book Value

• Annual Sales: $146,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.33) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 61,719,000
• Free Float: 61,700,000
• Market Cap: $833,000.00
• Optionable: No Data
• Beta: -0.90